Prognostic Value of Hyperuricemia on Clinical Outcomes of Sepsis:
DOI:
https://doi.org/10.63682/jns.v14i32S.7685Keywords:
Hyperuricemia, Sepsis, Septic shock, Mechanical ventilation, Vasopressor support, Mortality, AKI, Duration of stayAbstract
Background: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Recent studies suggest that metabolic disturbances, including hyperuricemia, may influence the clinical course of sepsis. Uric acid, an end product of purine metabolism, has pro-inflammatory properties that may exacerbate organ dysfunction in septic patients and hence used as a marker of poor prognosis in sepsis. Hyperuricemia and its potential association with poor clinical outcomes, such as acute kidney injury (AKI), need for vasopressor support, mechanical ventilation, and mortality, remains an area of growing interest. This study investigates the association between hyperuricemia and clinical outcomes in adult sepsis patients admitted to the Medical Intensive Care Unit (MICU).
Methods: This retrospective analytical study included 162 adult patients diagnosed with sepsis and admitted to the MICU of Karpaga Vinayaga Medical College Hospital, Chengalpattu, Tamil Nadu, India, between January 2024 and December 2024. Adult patients who met Sepsis-3 definition of sepsis is included in this study. Serum uric acid levels, Lactate levels, Creatinine value at the time of admission and after 24 hours of admission were noted. Serum Uric acid levels more than 7 mg/dL is considered as hyperuricemia. Patients were divided into hyperuricemia (n=107) and normouricemia (n=55) groups based on serum uric acid levels. Baseline characteristics, laboratory parameters, AKI, duration of hospital stay, need for vasopressor support, need for assisted mechanical ventilation and mortality outcomes were compared between the groups using appropriate statistical tests, including Fisher’s exact test and chi-square analysis.
Results: The median age was 59.5 years, with a female predominance (60.49%). Diabetes (58.02%) and hypertension (53.09%) were the most common comorbidities. Hyperuricemia was present in 66.04% of patients, with a mean serum uric acid level of 8.24 ± 3.13 mg/dL. AKI was significantly associated with hyperuricemia (p<0.0001). Elevated lactate levels (>2.2 mmol/L) were found in 98.13% of hyperuricemia patients, indicating hemodynamic instability. Vasopressor support was more frequently required in the hyperuricemia group, with 38% needing two or more vasopressors versus 16.7% in the normouricemia group (p<0.001). Additionally, 35.51% of hyperuricemia patients required mechanical ventilation compared to 3.63% in the normouricemia group (p<0.001). In-hospital mortality was also significantly higher in the hyperuricemia group (p=0.0194), although 30-day mortality did not reach statistical significance (p=0.2248).
Conclusion: Hyperuricemia in sepsis is significantly associated with worse clinical outcomes, including acute kidney injury, need for multiple vasopressors, assisted mechanical ventilation, and increased in-hospital mortality. Serum uric acid may serve as a useful biomarker for risk stratification in septic patients.
Downloads
Metrics
References
Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.;
Lakshmikanth CL, Jacob SP, Chaithra VH, de Castro-Faria-Neto HC, Marathe GK. Sepsis: in search of cure. Inflamm Res. 2016; 65(8):587-602.
Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012;10(6):701-706.
Ma J, Chen C, Barth AS, Cheadle C, Guan X, Gao L. Lysosome and cytoskeleton pathways are robustly enriched in the blood of septic patients: a meta-analysis of transcriptomic data. Mediators Inflamm. 2015;2015:984825.
Rossaint J, Zarbock A. Pathogenesis of multiple organ failure in sepsis. Crit Rev Immunol. 2015;35(4):277-291.
Liu, V.; Escobar, G.J.; Greene, J.D.; Soule, J.; Whippy, A.; Angus, D.C.; Iwashyna, T.J. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 2014, 312, 90–92. [CrossRef] [PubMed]
Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C.; Machado, F.R.; Mcintyre, L.; Ostermann, M.; Prescott, H.C.; et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021, 47, 1181–1247. [CrossRef] [PubMed]
Fox, I. H. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 30, 616–634 (1981).
Maxwell, S. R. et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 27, 484–490 (1997).
Perlstein, T. S. et al. Uric acid and the state of the intrarenal renin–angiotensin system in humans. Kidney Int. 66, 1465–1470 (2004).
W. Doehner, N. Schoene, M. Rauchhaus et al., “Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies,” Circulation, vol. 105, no. 22, pp. 2619–2624, 2002.
N. L. Edwards, “The role of hyperuricemia and gout in kidney and cardiovascular disease,” Cleveland Clinic Journal of Medicine, vol. 75, no. 5, pp. 13–16, 2008.
Mantzarlis K, Tsolaki V, Zakynthinos E. Role of oxidative stress and mitochondrial dysfunction in sepsis and potential therapies. Oxid Med Cell Longev 2017; 2017:5985209.
A. G. Ioachimescu, D.M. Brennan, B.M.Hoar, S. L.Hazen, and B. J. Hoogwerf, “Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a Preventive Cardiology Information System (PreCIS) database cohort study,” Arthritis and Rheumatism, vol. 58, no. 2, pp. 623–630, 2008.
D. B. Corry and M. L. Tuck, “Uric acid and the vasculature,” Current Hypertension Reports, vol. 8, no. 2, pp. 116–119, 2006.
P. Patetsios, W. Rodino, W. Wisselink, D. Bryan, J. D. Kirwin, And T. F. Panetta, “Identification of uric acid in aortic aneurysms and atherosclerotic artery,” Annals of the New York Academy of Sciences, vol. 800, pp. 243–245, 1996.
J. Fang and M. H. Alderman, “Serum uric acid and cardiovascular mortality, the NHANES I epidemiologic follow up study, 1971–1992,” Journal of the American Medical Association, vol. 283, no. 18, pp. 2404–2410, 2000.
P. Verdecchia, G. Schillaci, G. Reboldi, F. Santeusanio, C. Porcellati, and P. Brunetti, “Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA study,” Hypertension, vol. 36,no. 6, pp. 1072–1078, 2000.
T. Nakagawa, P. Cirillo,W. Sato et al., “The conundrum of hyperuricemia, metabolic syndrome, and renal disease,” Internal and Emergency Medicine, vol. 3, no. 4, pp. 313–318, 2008.
L. G. Hunsicker, S. Adler, A. Caggiula et al., “Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study,” Kidney International, vol. 51, no. 6, pp. 1908–1919, 1997.
K. Iseki, S. Oshiro, M. Tozawa, C. Iseki, Y. Ikemiya, and S. Takishita, “Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects,” Hypertension Research, vol. 24, no. 6, pp. 691–697, 2001.
F. Leyva, S. Anker, J.W. Swan et al., “Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure,”European Heart Journal, vol. 18, no. 5, pp. 858–865, 1997.
S. D. Anker, F. Leyva, P. A. Poole-Wilson, W. J. Kox, J. C. Stevenson, and A. J. S. Coats, “Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure,” Heart, vol. 78, no. 1, pp. 39–43, 1997.
A. Braghiroli, C. Sacco, M. Erbetta, V. Ruga, and C. F. Donner, “Overnight urinary uric acid: creatinine ratio for detection of sleep hypoxemia: Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure,” American Review of Respiratory Disease, vol. 148, no. 1, pp. 173–178, 1993.
N. M. Elsayed, J. M. Nakashima, and E. M. Postlethwait, “Measurement of uric acid as a marker of oxygen tension in the lung,” Archives of Biochemistry and Biophysics, vol. 302, no. 1, pp. 228–232, 1993.
A. Khwaja, “KDIGO clinical practice guidelines for acute kidney injury,” Nephron Clinical Practice, vol. 120, no. 4, pp. c179–c184, 2012.
Watanabe S et al. “Uric acid and the kidney: novel roles in diseases of renal and cardiovascular systems.” Curr Opin Nephrol Hypertens. 2011.
Ejaz AA et al. “Uric acid and acute kidney injury.” Semin Nephrol. 2011.
Lapsia V et al. “Hyperuricemia and acute kidney injury in hospitalized patients.” Kidney Int. 2012.
Kanbay M et al. “Uric acid as a potential physiological trigger for the induction of hypertension.” Hypertension. 2011.
George J et al. “Uric acid in inflammation and the pathogenesis of disease.” Rheumatology. 2006.
Kim SY et al. “Association of serum uric acid level with mortality and morbidity in sepsis.” Korean J Intern Med. 2013.
Wu Y et al. “Association between hyperuricemia and mortality in critically ill patients: a retrospective cohort study.” BMJ Open. 2021.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
